As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
HOME > REGULATORY
REGULATORY
- Japan, US, European Trade Groups Give Opinions on Govt’s CEA Proposal: Chuikyo
February 7, 2019
- Kymriah Up for MHLW Panel Review on Feb. 20 as Japan’s 1st CAR-T Therapy
February 6, 2019
- MHLW Informs of Outlines for New Package Insert Format to Be Introduced in April
February 6, 2019
- Key MHLW Panel Backs Iron Replacement Therapy Ferinject, No Vyvanse Review
February 1, 2019
- Faulty Wage Data Might Have Affected Drug Pricing as Labor Stats Used for Cost-Based Method
January 31, 2019
- Janssen’s Erleada Clears MHLW Panel Review, Now in Line for March Approval
January 31, 2019
- Pharmacies Fret Inventory Value Dip, Negative Margins due to Tax Hike-Linked Re-Pricing: Chuikyo Public Hearing
January 31, 2019
- MHLW Calls for Thorough Check on Drugs after Cyanide Blackmail
January 30, 2019
- PMDA Eyeing Staffer Increase of Around 150 over Next 5 Years, Official Suggests
January 29, 2019
- MSD to Tap MID-NET Database for Erelsa/Grazyna in 3rd Private Sector Use
January 29, 2019
- MHLW Revises Notifications on Electronic Data Submission as End of Grace Period Approaches
January 28, 2019
- Resistant Virus Found in Kids Administered Xofluza: NIID
January 28, 2019
- NITE, Genome Pharmaceuticals Institute Jointly Explore Rare Actinomycetes for MRSA
January 28, 2019
- “Detailed Discussions” Necessary for Use of Real World Data: HSC Panel
January 25, 2019
- MHLW Unveils Outline of Cost-Effective Assessment Scheme: Chuikyo
January 24, 2019
- Japan Fair Trade Watchdog Raids 2 Generic Makers on Suspicion of Price Fixing
January 23, 2019
- Maviret, Ibrance, PD-1 Inhibitors under PMDA Risk Review
January 21, 2019
- MHLW to Give Enough Preparation Time for Local Govts before New PMD Law Takes Effect
January 21, 2019
- Iron Deficiency Med Ferinject Up for MHLW Panel Review on Jan. 31; No Vyvanse Discussion This Time
January 18, 2019
- MHLW Panels Find No Major Safety Concern for 14 Vaccines: July-October
January 17, 2019
ページ
While grappling with sluggish revenues in Japan last year amid 1.7% negative market growth as put by IQVIA, mega pharma companies saw their upbeat oncology franchises increasingly buttress their businesses in the country, helping them soften the blows from generic…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…